AstraZeneca drew headlines Tuesday with an announcement that it is beginning Phase 1 trials of its monoclonal antibody treatment for COVID-19, while American Airlines said it would be laying off 19,000 employees by Oct. 1.
AstraZeneca’s AZD7442 antibody treatment uses antibodies from patients that have been infected with COVID-19 to treat and prevent the progression of the virus.
The trials by AstraZeneca are being conducted in the U.K. with 48 healthy patients aged 18-55 through funding by the Defense Advanced Research Projects Agency of the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority.
Following Phase 1 trials, AstraZeneca said it would move to larger, late-stage Phase 2 and Phase 3 trials if the results prove tolerable and favorable. Data is expected to be available in the second half of 2020.
“This trial is an important milestone in the development of our monoclonal antibody combination to prevent